Who owns Entrada Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of TRDA from SEC Form 13F filings across 132 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 132 institutions disclosed 30.9M shares of Entrada Therapeutics, Inc. worth $196.2M — about 73% of shares outstanding; the largest disclosed holder is BAKER BROS. ADVISORS LP. Source: SEC Form 13F filings, parsed by EvidInvest.
132
13F holders
$196.2M
value, 2026 filers
73%
of shares outstanding (30.9M sh)
18
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of TRDA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 5.1M | $32.2M | 0.2% | 12% | 0.0% |
| 2 | 5AM Venture Management, LLC | 3.8M | $24.0M | 8.1% | 8.9% | -6.7% |
| 3 | BlackRock, Inc. | 3.2M | $20.6M | 0.0% | 7.6% | +25.3% |
| 4 | Merck & Co., Inc. | 1.7M | $11.0M | 1.3% | 4.1% | 0.0% |
| 5 | Trails Edge Capital Partners, LPNEW | 1.4M | $9.1M | 1.3% | 3.4% | new |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $8.1M | 0.0% | 3% | 0.0% |
| 7 | TCG Crossover Management, LLC | 1.1M | $6.7M | 0.2% | 2.5% | 0.0% |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 954,419 | $6.1M | 0.0% | 2.3% | 0.0% |
| 9 | StepStone Group LP | 761,277 | $4.8M | 0.3% | 1.8% | 0.0% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 708,490 | $4.5M | 0.0% | 1.7% | -1.2% |
| 11 | ACADIAN ASSET MANAGEMENT LLC | 648,973 | $4.1M | 0.0% | 1.5% | +61.9% |
| 12 | UBS Group AG | 624,220 | $4.0M | 0.0% | 1.5% | +1401.8% |
| 13 | AQR CAPITAL MANAGEMENT LLC | 623,874 | $4.0M | 0.0% | 1.5% | -10.8% |
| 14 | STATE STREET CORP | 589,101 | $3.7M | 0.0% | 1.4% | -1.3% |
| 15 | JPMORGAN CHASE & CO | 506,591 | $3.2M | 0.0% | 1.2% | +2.0% |
| 16 | CITADEL ADVISORS LLC | 461,737 | $2.9M | 0.0% | 1.1% | +17.1% |
| 17 | MORGAN STANLEY | 386,243 | $2.5M | 0.0% | 0.9% | +101.5% |
| 18 | MILLENNIUM MANAGEMENT LLC | 344,603 | $2.2M | 0.0% | 0.8% | -54.9% |
| 19 | DIMENSIONAL FUND ADVISORS LP | 344,005 | $2.2M | 0.0% | 0.8% | -8.5% |
| 20 | NORTHERN TRUST CORP | 298,840 | $1.9M | 0.0% | 0.7% | -3.6% |
| 21 | GOLDMAN SACHS GROUP INC | 298,172 | $1.9M | 0.0% | 0.7% | +68.1% |
| 22 | Lynx1 Capital Management LP | 278,606 | $1.8M | 0.3% | 0.7% | +56.0% |
| 23 | J. Goldman & Co LPNEW | 268,081 | $1.7M | 0.0% | 0.6% | new |
| 24 | GSA CAPITAL PARTNERS LLP | 262,682 | $1.7M | 0.1% | 0.6% | +198.5% |
| 25 | VANGUARD PORTFOLIO MANAGEMENT LLC | 261,475 | $1.7M | 0.0% | 0.6% | +2.9% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.